All-cause mortality, cardiovascular readmission for myocardial infarction, heart failure, and stroke risk higher for PCI versus CABG
TUESDAY, Jan. 6, 2026 (HealthDay News) — For women with severe coronary artery disease (CAD), percutaneous coronary intervention (PCI) is associated with increased risks for major adverse cardiovascular and cerebrovascular events (MACCE) and all-cause mortality compared with coronary artery bypass grafting (CABG), according to a study published online Nov. 25 in the European Heart Journal.
Kevin R. An, M.D., M.P.H., from Sunnybrook Health Sciences Centre at the University of Toronto, and colleagues compared long-term outcomes of PCI and CABG in women with chronic severe CAD in a propensity score-matched retrospective cohort study. A total of 2,469 women underwent PCI and 3,721 underwent CABG; 2,033 pairs were identified after propensity score matching.
The researchers found that MACCE was higher with PCI versus CABG at a median follow-up of 5.1 years (hazard ratio, 1.81). Compared with CABG, all-cause mortality was higher with PCI (hazard ratio, 1.34), as was cardiovascular readmission (myocardial infarction, heart failure, or stroke; hazard ratio, 1.40).
“For now, treatment decisions should remain individualized,” An said in a statement. “Although our study suggests that bypass surgery may offer more long-term protection compared to stents, anatomical considerations, individual surgical risk, and patient preferences remain critical.”
Abstract/Full Text (subscription or payment may be required)
High Indoor Radon Levels Tied to Higher Risk for Heart Failure
Cannabis Legalization Linked to More Heart-Related Hospitalizations
Lower Cognitive Functioning During 60s Linked to Subsequent Stroke Risk
Exercise-Based Cardiac Rehab Beneficial for Coronary Heart Disease
Isometric Exercise Training Three Times a Week Preserves Cardiovascular Benefits
UACR, UPCR Provide Indistinguishable Prognostic Information in CKD
Strength Training Not Tied to Ventricular Arrhythmia in Those With Arrhythmogenic Cardiomyopathy
Use of SAMA, SABA Linked to Cardiovascular Events, Mortality in Asthma, COPD